300 related articles for article (PubMed ID: 33555117)
41. A case report: Pharmacology and resistance patterns of three generations of ALK inhibitors in metastatic inflammatory myofibroblastic sarcoma.
Parker BM; Parker JV; Lymperopoulos A; Konda V
J Oncol Pharm Pract; 2019 Jul; 25(5):1226-1230. PubMed ID: 29925295
[TBL] [Abstract][Full Text] [Related]
42. PLEKHM2-ALK: A novel fusion in small-cell lung cancer and durable response to ALK inhibitors.
Li T; Zhang F; Wu Z; Cui L; Zhao X; Wang J; Hu Y
Lung Cancer; 2020 Jan; 139():146-150. PubMed ID: 31794921
[TBL] [Abstract][Full Text] [Related]
43. A novel fusion of TPR and ALK in lung adenocarcinoma.
Choi YL; Lira ME; Hong M; Kim RN; Choi SJ; Song JY; Pandy K; Mann DL; Stahl JA; Peckham HE; Zheng Z; Han J; Mao M; Kim J
J Thorac Oncol; 2014 Apr; 9(4):563-6. PubMed ID: 24736082
[TBL] [Abstract][Full Text] [Related]
44. EML4-ALK, a potential therapeutic target that responds to alectinib in ovarian cancer.
Hui B; Zhang J; Shi X; Xing F; Shao YW; Wang Y; Zhang X; Wang S
Jpn J Clin Oncol; 2020 Dec; 50(12):1470-1474. PubMed ID: 32845005
[TBL] [Abstract][Full Text] [Related]
45. SEC31A-ALK Fusion Gene in Lung Adenocarcinoma.
Kim RN; Choi YL; Lee MS; Lira ME; Mao M; Mann D; Stahl J; Licon A; Choi SJ; Van Vrancken M; Han J; Wlodarska I; Kim J
Cancer Res Treat; 2016 Jan; 48(1):398-402. PubMed ID: 25715771
[TBL] [Abstract][Full Text] [Related]
46. STRN-ALK rearranged pediatric malignant peritoneal mesothelioma - Functional testing of 527 cancer drugs in patient-derived cancer cells.
Murumägi A; Ungureanu D; Arjama M; Bützow R; Lohi J; Sariola H; Kanerva J; Koskenvuo M; Kallioniemi O
Transl Oncol; 2021 Apr; 14(4):101027. PubMed ID: 33530027
[TBL] [Abstract][Full Text] [Related]
47. Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study.
Camidge DR; Dziadziuszko R; Peters S; Mok T; Noe J; Nowicka M; Gadgeel SM; Cheema P; Pavlakis N; de Marinis F; Cho BC; Zhang L; Moro-Sibilot D; Liu T; Bordogna W; Balas B; Müller B; Shaw AT
J Thorac Oncol; 2019 Jul; 14(7):1233-1243. PubMed ID: 30902613
[TBL] [Abstract][Full Text] [Related]
48. Quantitative detection of ALK fusion breakpoints in plasma cell-free DNA from patients with non-small cell lung cancer using PCR-based target sequencing with a tiling primer set and two-step mapping/alignment.
Kunimasa K; Kato K; Imamura F; Kukita Y
PLoS One; 2019; 14(9):e0222233. PubMed ID: 31513617
[TBL] [Abstract][Full Text] [Related]
49. Targeted next-generation sequencing revealed distinct clinicopathologic and molecular features of VCL-ALK RCC: A unique case from an older patient without clinical evidence of sickle cell trait.
Wang XT; Fang R; Ye SB; Zhang RS; Li R; Wang X; Ji RH; Lu ZF; Ma HH; Zhou XJ; Xia QY; Rao Q
Pathol Res Pract; 2019 Nov; 215(11):152651. PubMed ID: 31563285
[TBL] [Abstract][Full Text] [Related]
50. The clinical responses of TNIP2-ALK fusion variants to crizotinib in ALK-rearranged lung adenocarcinoma.
Feng T; Chen Z; Gu J; Wang Y; Zhang J; Min L
Lung Cancer; 2019 Nov; 137():19-22. PubMed ID: 31521978
[TBL] [Abstract][Full Text] [Related]
51. ALK detection in lung cancer: identification of atypical and cryptic ALK rearrangements using an optimal algorithm.
Liu Y; Wu S; Shi X; Liang Z; Zeng X
J Cancer Res Clin Oncol; 2020 May; 146(5):1307-1320. PubMed ID: 32128622
[TBL] [Abstract][Full Text] [Related]
52. Epithelioid fibrous histiocytoma: molecular characterization of ALK fusion partners in 23 cases.
Dickson BC; Swanson D; Charames GS; Fletcher CD; Hornick JL
Mod Pathol; 2018 May; 31(5):753-762. PubMed ID: 29327718
[TBL] [Abstract][Full Text] [Related]
53. Identification of Driving ALK Fusion Genes and Genomic Landscape of Medullary Thyroid Cancer.
Ji JH; Oh YL; Hong M; Yun JW; Lee HW; Kim D; Ji Y; Kim DH; Park WY; Shin HT; Kim KM; Ahn MJ; Park K; Sun JM
PLoS Genet; 2015 Aug; 11(8):e1005467. PubMed ID: 26295973
[TBL] [Abstract][Full Text] [Related]
54. A Subset of Malignant Mesotheliomas in Young Adults Are Associated With Recurrent EWSR1/FUS-ATF1 Fusions.
Desmeules P; Joubert P; Zhang L; Al-Ahmadie HA; Fletcher CD; Vakiani E; Delair DF; Rekhtman N; Ladanyi M; Travis WD; Antonescu CR
Am J Surg Pathol; 2017 Jul; 41(7):980-988. PubMed ID: 28505004
[TBL] [Abstract][Full Text] [Related]
55. Novel NTRK3 Fusions in Fibrosarcomas of Adults.
Yamazaki F; Nakatani F; Asano N; Wakai S; Sekimizu M; Mitani S; Kubo T; Kawai A; Ichikawa H; Yoshida A
Am J Surg Pathol; 2019 Apr; 43(4):523-530. PubMed ID: 30520818
[TBL] [Abstract][Full Text] [Related]
56. Identification of Targetable
Singhi AD; Ali SM; Lacy J; Hendifar A; Nguyen K; Koo J; Chung JH; Greenbowe J; Ross JS; Nikiforova MN; Zeh HJ; Sarkaria IS; Dasyam A; Bahary N
J Natl Compr Canc Netw; 2017 May; 15(5):555-562. PubMed ID: 28476735
[TBL] [Abstract][Full Text] [Related]
57. Expanding the Molecular Characterization of Thoracic Inflammatory Myofibroblastic Tumors beyond ALK Gene Rearrangements.
Chang JC; Zhang L; Drilon AE; Chi P; Alaggio R; Borsu L; Benayed R; Travis WD; Ladanyi M; Antonescu CR
J Thorac Oncol; 2019 May; 14(5):825-834. PubMed ID: 30550870
[TBL] [Abstract][Full Text] [Related]
58. MPRIP-ALK, a Novel ALK Rearrangement That Responds to ALK Inhibition in NSCLC.
Fang W; Gan J; Hong S; Lu F; Zhang L
J Thorac Oncol; 2019 Jul; 14(7):e148-e151. PubMed ID: 31235041
[No Abstract] [Full Text] [Related]
59. Expression of C-terminal ALK, RET, or ROS1 in lung cancer cells with or without fusion.
Furugaki K; Mochizuki M; Kohno M; Shu S; Harada N; Yoshimura Y
BMC Cancer; 2019 Apr; 19(1):301. PubMed ID: 30943926
[TBL] [Abstract][Full Text] [Related]
60. Molecular investigation of ALK-rearranged epithelioid fibrous histiocytomas identifies CLTC as a novel fusion partner and evidence of fusion-independent transcription activation.
Georgantzoglou N; Green D; Winnick KN; Sumegi J; Charville GW; Bridge JA; Linos K
Genes Chromosomes Cancer; 2022 Aug; 61(8):471-480. PubMed ID: 35289445
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
